ClinicalTrials.gg
CompletedNCT05256108Updated Jul 27, 2022

Assessment of Abuse Potential of Cebranopadol in Humans

A Phase 1 interventional study of Oxycodone 40 mg and Tramadol 600 mg in Human Abuse Potential, sponsored by Tris Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-27.

Sponsored by Tris Pharma, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2022, 4 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,882 studies in Pain with a site in United States — 313 open to participants now, 392 under way, 24 of them phase 3. Pain · United States.

Enrollment
1,735th of 2,560
38 · median 66
Started
2022
with 93 others
Phase 1
206 of 2,882
28 open now
Registered
2,338th of 2,882
by date

Among the 2,882 studies in Pain with a site in United States, this one is the 1,735th largest by enrollment of the 2,560 interventional ones that give a count, is one of 94 that started in 2022, is one of 206 in phase 1, and was the 2,338th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

313 of the 2,882 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

308 more — sign in →

All 313 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,882 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

This study will be conducted to evaluate the abuse potential of single doses of cebranopadol as compared with oxycodone, tramadol and matching placebo in recreational drug users.

Read the detailed description

Randomized, single site, double-blind, placebo- and active-controlled, crossover, single oral dose, Phase 1 trial, in non dependent recreational opioid users

03

Conditions studied

  • Human Abuse Potential

Browse trials for

Keywords

  • pain
  • abuse
  • opioid
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Willing and able to provide written
  • Adult men or women aged 18 to 55 years, inclusive
  • History of recreational opioid use defined as non therapeutic use at least 10 times in the subject's lifetime and at least once in the 12 weeks prior to the Enrollment Visit
  • between 19 kg/m2 and 32 kg/m2 inclusive, with a body weight of not less than 50 kg at Enrollment
  • Subjects must be in good health as determined by medical history, physical examination, 12 lead (ECG), and vital signs (pulse rate, systolic blood pressure and diastolic blood pressure, respiratory rate, and oxygen saturation using pulse oximetry) at Enrollment

Exclusion Criteria:

  • Exclusion Criteria for Enrollment:
  • Self-reported history of drug or alcohol dependence (lifetime) other than caffeine or nicotine as defined by DSM IV-TR criteria
  • Current treatment or treatment within their lifetime for substance disorders, other than treatment for smoking cessation
  • Positive or missing alcohol breath test at Enrollment; the alcohol breath test can be repeated and/or the subject rescheduled at the discretion of the investigator or designee
  • Pregnant or breastfeeding or missing pregnancy test
  • Unwillingness or inability to abstain from recreational drug use for the duration of the trial
  • Current consumption of greater than 20 cigarettes per day or inability to abstain from smoking (or use of any nicotine-containing substance) for at least 8 hours
  • Participation in another clinical trial within 30 days prior to Enrollment that resulted in the administration of at least 1 dose of IMP
  • Diseases or conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs. Subjects with a history of cholecystectomy are not excluded
  • Prolongation of (after repeated assessment) at Enrollment, i.e., >450 ms for men or >470 ms for women, or presence of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia), or use of concomitant medications that prolong the QT interval
  • History of orthostatic hypotension or other cardiovascular diseases
  • Any disease that in the investigator's opinion may affect efficacy or safety assessments or may compromise the subject's safety during trial participation, e.g., significant pulmonary, gastrointestinal, cardiac, endocrine, metabolic, neurological, or psychiatric disorders
  • Definite or suspected history of drug allergy or to opioids or opioid antagonists
  • Use of prescription medications within the longer of 14 days or 5 half-lives or use of over-the-counter medications within the longer of 7 days or 5 half-lives prior to dosing, exceptions may be made on a case-by-case basis (e.g., for medications with a short half-life or for topical medications) if approved by the medical monitor in agreement with the investigator
  • Any for naloxone, oxycodone IR, or tramadol IR administration
  • Not able to abstain from consumption of beverages or food containing caffeine (tea, coffee, cola, chocolate, etc.) or alcohol from 2 days prior to each Day 1 until discharge from the research unit; beverages or food containing quinine (e.g., bitter lemon, tonic water) from 1 week before Day 1 of the Qualification Phase until the final examination; grapefruit juice (sweet or sour) or Seville oranges from 1 week before Day 1 of the Qualification Phase until the final examination.
  • Blood loss of 500 mL or more within 4 weeks before dosing in the treatment phase in this trial, including blood donation. Planned blood donations during the trial and up to 12 weeks after the Final Examination
  • History of seizure disorder including unprovoked seizure and/or epilepsy or any condition associated with a significant risk for seizure disorder or epilepsy at the Enrollment Visit at the discretion of the investigator
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Cebranopadol 600 µg

    Single oral dose of 6 capsules containing 3 cebranopadol 200 µg tablets and placebo

    Drug: Cebranopadol 600 µg

  • Experimental
    Cebranopadol 1000 µg

    Single oral dose of 6 capsules containing 5 cebranopadol 200 µg tablets and placebo

    Drug: Cebranopadol 1000 µg

  • Active comparator
    Oxycodone 40 mg

    Single oral dose of 6 capsules containing 2 oxycodone 20 mg and placebo

    Drug: Oxycodone 40 mg

  • Active comparator
    Tramadol 600 mg

    Single oral dose of 6 capsules containing 6 tramadol 100 mg tablets

    Drug: Tramadol 600 mg

  • Placebo comparator
    Placebo

    Single oral dose of 6 capsules containing placebo

    Drug: Placebo

Interventions

  • Participants will be administered a single dose of 6 capsules containing oxycodone and placebo in a randomized crossover manner

    Also known as: Qualification Phase/ Treatment Phase

  • Participants will be administered a single dose of 6 capsules containing tramadol in a randomized crossover manner

    Also known as: Qualification Phase/ Treatment Phase

  • DrugPlacebo

    Participants will be administered a single dose of 6 capsules containing placebo in a randomized crossover manner

    Also known as: Qualification Phase/ Treatment Phase

  • Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner

    Also known as: Treatment Phase

  • Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner

    Also known as: Treatment Phase

06

What researchers measure

Primary outcomes

  1. Drug Liking Visual analog scale (VAS) Emax

    The scale is a 0-100-point scale: 0 = "Strong disliking"; 50 = "Neither like nor dislike"; 100 = "Strong liking"

    Time frame: Treatment Phase: Intervals from predose to 48 hours post-dose

Secondary outcomes

  1. VAS rating for Overall Liking

    The scale is a 0-100-point scale: 0 = "Strong Disliking", 50 = "Neither Like nor Dislike", 100 = "Strong Liking"

    Time frame: Treatment Phase: Intervals from predose to 48 hours post-dose

  2. VAS rating for Take Drug Again

    The scale is a 0-100-point scale: 0 = "Definitely would not"; 50 = "Do not care"; 100 = "Definitely would"

    Time frame: Treatment Phase: Intervals from predose to 48 hours post-dose

  3. Pupillometry

    Data from a series of frames will be used in the calculation, and the final display will show the weighted average and standard deviation of the pupil size. Measurements will be collected under mesopic lighting conditions

    Time frame: Treatment Phase: Intervals from predose to 48 hours post-dose

  4. Multi-Tasking Test

    Formerly known as the Attention Switching Task (AST), is a test of executive function which provides a measure of the ability to use multiple sources of potentially conflicting information to guide behavior.

    Time frame: Treatment Phase: Intervals from predose to 48 hours post-dose

07

Study locations

1 site
  • Ohio Clinical Trials
    Columbus, Ohio 43212, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Jul 2022, 3 months.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 3 months is below that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2022
First posted
Feb 25, 2022
StartActual
Mar 28, 2022
Primary completionActual
Jul 12, 2022
CompletionActual
Jul 12, 2022
Last update
Jul 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05256108
Lead sponsor
Tris Pharma, Inc.
Responsible party
Sponsor
First posted
Feb 25, 2022
Start date
Mar 28, 2022
Primary completion
Jul 12, 2022
Completion
Jul 12, 2022
Last update
Jul 27, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cebranopadol

Start the discussion